NXT

NXT Biologics is a biotechnology company focused on developing first-in-class vaccines and therapeutics for life-threatening fungal infections. Spun out from research at the University of Georgia, the company’s lead program is NXT-2, a pan-fungal vaccine candidate designed to target the conserved Kexin (KEX1) protein found in a wide range of fungal pathogens, including Pneumocystis, Aspergillus, and Candida. In addition to its vaccine programs, NXT Biologics is advancing a pipeline of therapeutic monoclonal antibodies and innovative diagnostic tools to address significant unmet medical needs in immunocompromised populations. The company aims to provide proactive protection and improved treatment options for patients at high risk of invasive fungal diseases.